Drug
Norelgestromin clinical trials
- studies test it
- 7
- open now
- 1
- in phase 3
- 2
- first study started
- 1997
Keep track of what changes. Save the norelgestromin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
6 studies that test it; most in 1997 (2)
| Year | Studies |
|---|---|
| 1997 | 2 |
| 2002 | 1 |
| 2003 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 2
- Phase 3
- 2
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 2
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. (1) · Janssen Pharmaceutica N.V., Belgium (1) · Janssen-Ortho Inc., Canada (1) · University of Vermont (1) · Chulalongkorn University (1)
Often tested with
Tested in the same studies.
Ethinyl Estradiol (7) · Ethinyl estradiol-desogestrel combination (1) · Norgestimate (1)
Studies
Open first, then newest update. How each study uses norelgestromin is read from its arms, and is right about nine times in ten.
Testing it · 7
- Transdermal Ethinyl Estradiol and Norelgestromin for Irregular Bleeding in Contraceptive Implant UsersRecruitingPhase 2Chulalongkorn UniversityNCT07083635Written as Transdermal Ethinyl Estradiol/Norelgestromin Patch
- An Open-Label Study to Compare the Bleeding Profile of Norelgestromin/Ethinyl Estradiol in an Extended Regimen to Norelgestromin/Ethinyl Estradiol Given in a Traditional RegimenCompletedPhase 2McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.NCT00320580Written as norelgestromin/ethinyl estradiol
- A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.CompletedPhase 3Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT00236782Written as norelgestromin + ethinyl estradiol; mercilon
- A Study of Efficacy and Safety With the Transdermal Contraceptive System.CompletedPhase 3Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT00236769Written as norelgestromin + ethinyl estradiol
- Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.CompletedPhase 4Janssen Pharmaceutica N.V., BelgiumNCT00261482Written as norelgestromin + ethinyl estradiol
- An Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contraceptive Patch vs. Previous Primary Contraceptive MethodCompletedPhase 4Janssen-Ortho Inc., CanadaNCT00653016Written as norelgestromin; ethinyl estradiol
- Birth Control Pill vs Birth Control Patch StudyCompletedNot applicableUniversity of VermontNCT00554632Written as Ethinyl estradiol and norelgestromin
As the comparator · 1 — what is tested is compared with norelgestromin
Codes
What other systems call norelgestromin · ClinicalTrials.gg INT004430
- MeSH (NLM) C449219norelgestrominConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) R0TAY3X631NORELGESTROMINConfirmed FDA, NLM
- RxNorm 326374One source FDA
- NCI Thesaurus C66243NorelgestrominOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C449219 | norelgestromin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | R0TAY3X631 | NORELGESTROMIN | Confirmed FDA, NLM |
| RxNorm | 326374 | — | One source FDA |
| NCI Thesaurus | C66243 | Norelgestromin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.